Valneva SE (VALN) Net Income (2021 - 2026)
Valneva SE (VALN) posted quarterly Net Income of -$34.6 million for Q1 2026, down 384.17% year-on-year from $12.2 million in Q1 2025, and up 39.25% on a QoQ basis from -$57.0 million in Q4 2025.
Valneva SE (VALN) Net Income (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Net Income for 6 consecutive years, with -$34.6 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income fell 384.17% year-over-year to -$34.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$158.6 million (down 79.83% YoY) and the FY2025 annual result came in at -$131.1 million, down 837.81% from the prior year.
- Net Income improved to -$34.6 million in Q1 2026 per VALN's latest filing, from -$57.0 million in the prior quarter.
- Over the last five years, Net Income for VALN reached as high as $307.9 million in Q3 2022 and fell as low as -$275.8 million in Q4 2022.
- A 5-year average of -$26.4 million and a median of -$32.9 million in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2024 — Net Income surged 225.07% — and 2025, when it slumped 426.23%.
- Year by year, Net Income stood at -$275.8 million in 2022, then surged by 87.64% to -$34.1 million in 2023, then slipped by 23.69% to -$42.2 million in 2024, then sank by 35.17% to -$57.0 million in 2025, then soared by 39.25% to -$34.6 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$34.6 million, -$57.0 million, and -$53.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -34.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.62 Mn |
| Dec 31, 2025 | -56.99 Mn |
| Sep 30, 2025 | -53.28 Mn |
| Jun 30, 2025 | -13.69 Mn |
| Mar 31, 2025 | -7.15 Mn |
| Dec 31, 2024 | -42.16 Mn |
| Sep 30, 2024 | -10.13 Mn |
| Jun 30, 2024 | -28.75 Mn |
| Mar 31, 2024 | 67.06 Mn |
| Dec 31, 2023 | -34.08 Mn |
| Sep 30, 2023 | -32.86 Mn |
| Jun 30, 2023 | -60.51 Mn |
| Mar 31, 2023 | 20.63 Mn |
| Dec 31, 2022 | -275.79 Mn |
| Sep 30, 2022 | 307.89 Mn |
| Jun 30, 2022 | -165.52 Mn |
| Mar 31, 2022 | -29.63 Mn |
| Dec 31, 2021 | -363.41 Mn |
| Sep 30, 2021 | 181.54 Mn |
| Jun 30, 2021 | 66.79 Mn |